Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.63 |
| ▸ | ACACB | O00763 | 3/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | TPH1 | P17752 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18244721 | 1.00 | ITGB3 (0.63) | ITGB3ITGA2BACACBSLC7A5PTPN1 | |
| SCHEMBL1712530 | 1.00 | ITGB3 (0.63) | ITGB3ITGA2BACACBSLC7A5PTPN1 | |
| SCHEMBL16163350 | 0.96 | ITGB3 (0.68) | ITGB3ITGA2BACACBSLC7A5PTPN1 | |
| SCHEMBL21095635 | 0.95 | ITGB3 (0.57) | ITGB3ITGA2BACACBSLC7A5PTPN1 | |
| SCHEMBL21556940 | 0.89 | ITGB3 (0.70) | ITGB3ITGA2BACACBSLC7A5PTPN1 | |
| SCHEMBL27654977 | 0.88 | ITGB3 (0.77) | ITGB3ITGA2BSLC7A5PTPN1ALPI | |
| SCHEMBL27268099 | 0.88 | ACACB (0.54) | ITGB3ITGA2BACACBPPARGPPARD | |
| SCHEMBL31329374 | 0.86 | ITGB3 (0.60) | ITGB3ITGA2BACACBSLC7A5PTPN1 | |
| SCHEMBL8953657 | 0.84 | ACACB (0.50) | ITGB3ITGA2BACACBPPARGPPARD | |
| SCHEMBL7512809 | 0.84 | ACACB (0.50) | ITGB3ITGA2BACACBPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344529-B1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA SAS (FR) | 2013-06-05 | — | — | EP | claimed |
| EP-2168983-A1 | New octapeptide compounds and their therapeutic use | IPSEN PHARMA (FR) | 2010-03-31 | — | — | EP | claimed |
| US-20230295190-A1 | Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof | TAE LIFE SCIENCES LLC | 2023-09-21 | — | — | US | disclosed |
| US-9382306-B2 | Octapeptide compounds derived from somatostatin and the therapeutic use thereof | IPSEN PHARMA S.A.S. (FR) | 2016-07-05 | — | — | US | disclosed |
| EP-2344529-B1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA SAS (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2344529-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037930-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2010-04-08 | — | — | WO | disclosed |
| EP-2168983-A1 | New octapeptide compounds and their therapeutic use | IPSEN PHARMA (FR) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | SSTR5, SSTR1, SSTR3 | ITGB3 3808/4885ITGA2B 4377/4885ACACB 4724/4885 |
| US-20230295190-A1 | Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof | BCAT2, BCAT1, SLC1A5 | ITGB3 2886/4885ITGA2B 1758/4885ACACB 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.